Navigation Links
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Date:6/26/2009

mission but they have not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the shelf registration statement becomes effective and a final receipt has been issued for the MJDS prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus and a related prospectus supplement.

A written preliminary prospectus included in the registration statement or MJDS prospectus, when available, and meeting the requirements of Section 10 of the Securities Act of 1933, as amended, may be obtained at the SEC's website http://www.sec.gov/ , through OncoGenex' website at http://www.oncogenex.com , or via written request to OncoGenex Pharmaceuticals, Inc. at OncoGenex Pharmaceuticals, Inc. at 1522 217th Place SE, Suite 100, Bothell, Washington 98021 U.S.A., Attn: Steve Anderson, Chief Financial Officer, or by telephoning (425) 686-1500. In addition, OncoGenex intends to file a prospectus supplement with the SEC in connection with future offerings, if any, under the shelf registration statement.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
4. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
5. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
6. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
7. OncoGenex Reports First Quarter Financial Results
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
10. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Rancho BioSciences , the ... Omicsoft’s Array Suite with tranSMART . Scientists ... to send data in tranSMART to Array Suite for ... of tranSMART including the new 1.2 release. Array ... storage for the analysis of high dimensional quantification data, ...
(Date:7/31/2014)... Although RNA-Sequencing is a relatively ... analyses appearing around 2008, RNA-Sequencing has rapidly evolved ... In the last several years, assays have improved ... smaller input amounts, process degraded RNA, and perform ... the bioinformatics side, there have been improvements in ...
(Date:7/31/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, August 7, 2014, and that ... webcast at 4:30 p.m. ET that afternoon. Management will ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
Breaking Biology Technology:Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2
... had the opportunity to discuss the role of technology ... based services - internally and externally for constituents. The ... investment funding and health insurance. He also shared his ... to limit unsolicited e-mail. , , WTN: ...
... with two research grants coming over the transom almost at ... non-profit subsidiary of the Wisconsin Alumni Research Foundation (WARF), ... of human embryonic stem cells. , ,The grant and ... Embryonic Stem Cell Research come from the National Institute ...
... at Menasha Advantage, a subsidiary of Neenahs Menasha Corp., ... Skunkworks. There, a better cardboard box is being born. ... Advantage is building a system to track shipments from ... Internet-based system will save time, money and headaches for ...
Cached Biology Technology:WTN Interview with Governor Doyle 2WTN Interview with Governor Doyle 3WTN Interview with Governor Doyle 4WTN Interview with Governor Doyle 5WTN Interview with Governor Doyle 6Double header for research dollars from Washington 2E-Commerce Skunkworks in Menhasa 2E-Commerce Skunkworks in Menhasa 3
(Date:8/1/2014)... of the most diverse families in the ocean today ... -- originated more than 400 million years ago in ... those of its modern members. This Geology ... published online on 25 July 2014, tracks the remarkable ... , At is origin, the Lucinidae family remained at ...
(Date:8/1/2014)... Research Institute (TSRI) have identified a signaling pathway that ... cells. , The study, which is reported in ... of the National Academy of Sciences , sheds light ... is of great interest to medical researchers because it ... diabetes. , "This finding offers new possibilities for the ...
(Date:8/1/2014)... may soon have a more effective way to control ... researchers from the National University of Singapore (NUS). , ... the Department of Pharmacology at the NUS Yong Loo ... Wanxing, a recent PhD graduate from the Saw Swee ... artesunate, a common herbal-based anti-malarial drug, can be used ...
Breaking Biology News(10 mins):Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14Scripps Research Institute scientists find new calorie-burning switch in brown fat 2Scripps Research Institute scientists find new calorie-burning switch in brown fat 3NUS study shows effectiveness of common anti-malarial drug in controlling asthma 2
... bypass, the most common type of bariatric surgery in ... therapy for morbid obesity. Patients who undergo this procedure, ... pouch and connected to the middle of the small ... reasons behind this surgery,s success have been unclear. Shedding ...
... -- July 26, 2011 - The Guy Harvey Ocean ... Neil Hammerschlag, Ph.D., director of the RJ Dunlap Marine ... research "Assessing the Cascading Ecosystem Impacts of Marine Apex ... of declining populations of tunas, billfish and sharks on ...
... to decide what to eat for dinner. Should it be ... entirely and just get some Rocky Road? Making that ... according to researchers from the California Institute of Technology (Caltech), ... of attention toward the healthy side of life. And that ...
Cached Biology News:Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 2Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 3Think healthy, eat healthy: Caltech scientists show link between attention and self-control 2Think healthy, eat healthy: Caltech scientists show link between attention and self-control 3Think healthy, eat healthy: Caltech scientists show link between attention and self-control 4
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
... Synthetic peptide derived from the C terminal ... This peptide sequence is downstream from ... polyclonal Connexin 36 antibody Cat. No. 51-6300. ... Reactivity: Mouse (positive control: mouse Connexin ...
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: